Human genome editing. TAB-Fokus by Albrecht, Steffen et al.
Client







TAB-Fokus no. 30 regarding report no. 191 September 2021
OFFICE OF TECHNOLOGY ASSESSMENT 














research on genome editing in plant and animal breeding 
as well as in human medicine. With regard to the potential 
application of human germline genome editing, an intense 
scientific and, to some extent, broader public controversy has 
developed – culminating in the reactions to the clinical ex-
periments in China that became public in November 2018. In 
this context, basic biomedical and moral objections to such 
transgenerational genome modifications are being discussed. 
In contrast, the discussion on somatic gene therapy using 
genome editing focuses on the hopes of improving and ex-
panding gene therapy options. For both somatic applications 
and germline interventions, there is also a need to consider the 
safety of application, i. e. the precision and the predictability 
of undesirable side effects.
Genome editing techniques
Since the mid-1990s, zinc finger nucleases and transcription 
activator-like effector nucleases (TALENs) have been devel-
oped. They combine functions for recognising a specific DNA 
sequence and cutting the double-stranded DNA molecule at 
that site. Genome editing tools based on the CRISPR-Cas9 
system have been under development since 2012. Their de-
velopment is much easier, faster and cost-efficient due to the 
use of RNA molecules instead of proteins for DNA sequence 
recognition. Moreover, they allow cutting at multiple sites at 
the same time.
Despite specific targeting of DNA target sequences, the 
application of genome editing can result in unintended 
changes at sites in the genome other than the actual target 
sequence (off-target effects). This can lead to an inactivation 
of genes and their function, to changes in the amount of 
gene products or to rearrangement of different chromosome 
Summary
 › Genome editing, a new set of methods of genetic engi-
neering, enables targeted interventions in somatic as well 
as in germline cells in humans.
 › Genome editing can help improve somatic gene therapies 
and expand their scope of application. Initial approaches 
are currently being tested in clinical trials.
 › Research and innovation policy impulses are needed for 
the development of gene- and cell-based therapies, par-
ticularly for rare diseases. The costs of the procedures 
likely will remain high. Accordingly, novel reimburse-
ment models are needed.
 › Unresolved health risks and fundamental ethical issues 
preclude a clinical application of germline interventions.
What is involved
Genome editing refers to the latest variant of genetic engineer-
ing. These molecular biological tools can be used to target a 
specific site in a cell’s genome and induce a DNA strand break 
there. This activates cellular repair mechanisms that can be 
used to modify gene sequences. Newer variants of genome 
editing allow the targeted conversion of individual or multiple 
DNA components – the bases – at the respective site.
Compared to previous techniques, genome editing enables 
more diverse and precise modifications in the genome of a 
wide variety of cell types, including fertilised eggs. Particularly 
with methods based on the CRISPR-Cas9 system, interven-
tions in the genome can be made quite easily, quickly and 
cost-efficiently. With genome editing, targeted and heritable 
interventions in the human germline, i. e. modifications of 
germ cells and embryos, are conceivable for the first time. 
Most importantly, genome editing is capable of and intended 
for improving and expanding gene- and cell-based therapies 
in other (somatic) cells of the body.
The discovery of the CRISPR-Cas9 system as a genome editing 
technique was awarded the Nobel Prize in Chemistry in 2020. 
For several years already, there has been a veritable boom in 
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sequences have to be altered (e. g. Huntington’s disease). In 
principle, thanks to genome editing, even interventions in 
gene regulation and an inactivation of genes become pos-
sible. This potentially enables new gene therapy applications 
(e. g. in therapies against the blood disease β-thalassemia as 
well as cancer immunotherapies).
First clinical trials applying genome editing have been start-
ed. In Germany, for example, a patient with β-thalassemia 
is being treated. As with conventional approaches, the com-
paratively inefficient and only partially tissue-specific gene 
transfer represents a challenge. Thus, some hereditary dis-
eases currently cannot be treated efficiently or at all with so-
matic gene therapy approaches. This is particularly the case 
for diseases that cause damage in several organs, some of 
which might be difficult to reach with genome editing tools 
(cystic fibrosis, muscular dystrophies), but also for diseases 
(e. g. certain metabolic diseases) in which a gene mutation 
leads to severe or irreversible damage at a very early stage 
(e. g. already in utero or at the time of birth). Challenges also 
arise for genome editing approaches due to off-target effects, 
unintended damage at the target site (on target), and im-
mune responses to the editing tools (derived from bacteria).
In Germany, there are established medical laws to ensure 
safety of application. From an ethical and social perspective, 
another issue to address is equitable access to gene therapies, 
which are expected to remain very expensive and pose a 
challenge to the existing drug reimbursement system.
It is genome editing that made possible targeted genetic mod-
ifications of germline cells in the first place. With these mod-
ifications, all cells of a developing organism can potentially be 
reached at the earliest possible point in time. This would allow 
gene therapies to be used even in cases that cannot be treated 
efficiently or even at all with somatic gene therapies.
Results of corresponding experiments on human embryos 
were first published in 2015. China apparently saw the birth 
of at least one pair of twins with altered genomes in 2018. 
So far, there has been no independent confirmation of this 
experiment, which was conducted in violation of applicable 
legal regulations and ethical requirements. Due to the low 
editing efficiency and the risk of off-target mutations, but 
also due to the insufficient knowledge about the interaction 
of human genes, initially only those applications of herit-
able genome editing appear to be technically feasible that 
would require the modification or correction of a single 
gene. These applications include:
 › preventing the transmission of monogenic diseases in 
couples for whom pre-implantation genetic diagnosis 
(PGD) is not promising (because no embryos or too 
few embryos without a genetic defect would result from 
which to select);
segments (translocations). Even at the targeted sites, there 
is only limited control over the mechanisms by which the 
cell repairs the double-strand break. Unplanned insertions 
or (sometimes very extensive) removals of genetic infor-
mation might occur, so that – although an inactivation of 
gene functions can often be achieved – a targeted sequence 
modification or a targeted insertion or exchange of genes 
still represent challenges.
Two other tools based on the CRISPR-Cas9 system – base 
and prime editing – do not cut the entire double-stranded 
DNA molecule, but use a modified Cas protein that unravels 
only a single strand. By means of further enzymes inserted 
into the tools, one base is converted into another at a specific 
site (base editing) or RNA molecules provided are converted 
into the desired sequence of DNA molecules and inserted 
into the strand (prime editing). Both methods promise fewer 
undesirable side effects (fewer off-target effects) and more 
control over the modification of genetic information. Prime 
editing in particular, however, has so far only been used on 
an experimental basis in the laboratory.
Potential applications in humans
Genome editing tools can be used both in basic and pre-
clinical research to investigate the role of individual genes 
in basal cellular and medically relevant processes on a ge-
nome-wide scale and to identify new target molecules for 
drugs. Moreover, models for researching diseases in animals 
and human cells can be created in a more differentiated way 
than before (e. g., through research on induced pluripotent 
stem cells and organoids instead of living organisms). Fi-
nally, researchers hope to gain a better understanding of the 
causes of infertility resulting from early embryonic arrest 
by performing functional analyses of genes in early human 
embryos. In Germany, however, research on human embry-
os is prohibited by the Embryo Protection Act. Particularly 
parts of the scientific community call for relaxing the pro-
hibition in order to be able to achieve research goals, such 
as a better understanding of early embryonic development. 
Corresponding findings from animal experiments can only 
be transferred to humans to a limited extent.
In the field of somatic gene therapy, several therapies for 
monogenic diseases and cancers have been approved in Eu-
rope and the USA in recent years. These are based on the 
random addition of genes into body cells. Genome editing 
techniques allow for a more targeted insertion of genes into 
the genome. They are intended to reduce the risk of inser-
tional mutagenesis, due to which intact genetic structures are 
unintentionally disrupted in their function (e. g. switched off 
or unintentionally activated), thus making therapies more 
efficient and safer. Moreover, for the first time, it is theo-
retically possible to treat diseases for which existing gene 




› improving/enabling the therapy
of monogenic diseases
› enabling intrauterine therapy of
inherited diseases that manifest
very early or multi-organically




What is the purpose of the intervention?
enabling ...
› therapies for monogenic diseases
› therapies for inherited diseases
that manifest very early or multi-
organically
› corrections of gene variants 
associated with high disease risks
› therapies for infertility
› in the body (in vivo) or in cells
obtained from the body (ex vivo)
How is the intervention carried out?
› in single-cell embryos or during
fertilisation (in vitro)
› only the treated person
Who is affected?
› also descendants
Where does the intervention take place?
› in cells of the body that do not
develop/give rise to gametes






 › the preventive modification of gene variants that are asso-
ciated with a very high risk of disease (e. g. mutations that 
can cause breast and ovarian cancer), provided that em-
bryos without such mutations can only be obtained with 
a low probability or not at all;
 › approaches to eliminate early embryonic arrests (when cells 
fail to proliferate due to single gene defects after in vitro fer-
tilisation) in egg precursor cells or fertilised eggs, provided 
the causes can be traced back to single genes.
Corresponding cases in which the less risky PGD cannot 
be used are still extremely rare. Genetic enhancement – i. e. 
using germline interventions without medical indication 
with the intention of improving certain traits  – appears 
unrealistic for the foreseeable future, because too little is 
known about the effect of gene variants and their interac-
tion, especially with regard to complex traits such as cog-
nitive abilities.
Legal and ethical assess- 
ment of germline 
interventions
Regardless of their intended use, 
germline interventions are almost 
unanimously and internationally 
regarded as ethically unaccept-
able, because safe use is not yet 
guaranteed. Particularly off-tar-
get effects and mosaicism (cells 
of one organism having differ-
ent genetic information) repre-
sent health risks to potential ge-
nome-edited children as well as 
to subsequent generations. In the 
case of germline interventions, 
standards of medical ethics – such 
as obtaining informed consent 
from those treated  – cannot be 
complied with in the traditional 
sense, and health consequences 
would have to be monitored over 
several generations.
Health risks are also the central 
reason for the ban on germline 
interventions in Germany, 
which is based on the Embryo 
Protection Act. New medical 
procedures such as nuclear trans-
fer and the production of germ 
cells from induced pluripotent 
stem cells, which also appears 
possible in humans in the future, 
might result in regulatory gaps 
in the Embryo Protection Act. 
So far, however, these gaps have 
no discernible practical relevance 
and could presumably be closed 
quickly. At the international level, there are bans on clini-
cal germline interventions in many countries, but these are 
often not based on laws or not clearly formulated. In 2018, 
an expert committee was established at the World Health 
Organization (WHO) to develop global governance mech-
anisms for genome editing in humans.
Fundamental ethical objections to germline interventions 
are justified by the interference with the right to self-deter-
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mination or the personal rights of still unborn human be-
ings. Some involved in the debate also fear that germline 
interventions could call into question basic preconditions of 
sociality, namely the autonomy that humans as social beings 
reciprocally assume. Moreover, the establishment of certain 
normative ideas regarding the genetic make-up of humans 
might encourage discrimination against people who deviate 
from these ideas. In favour of germline interventions, it is 
pointed out that these may be a preferable or even the only 
option for affected people to have genetically related children 
without hereditary diseases.
Options for action
In the field of somatic gene- and cell-based therapies, ge-
nome editing techniques have spurred a variety of research 
and development activities in order to improve existing ap-
proaches or to develop new ones. First clinical trials have 
already begun. In the years to come, there will be tangible 
opportunities for political action in terms of public sup-
port for research and development, for example through 
tax benefits for R&D investments and mega-fund models 
for financing high-risk but potentially high-profit projects. 
Given that costs are likely to remain high in most cases, 
existing reimbursement models could be supplemented 
with performance-based models and the effect of innova-
tion incentives on drug development for rare diseases could 
be investigated more closely.
In comparison, the future way of dealing with possible 
germline interventions is much more the subject of polit-
ical and societal debates. However, the number of realistic 
application scenarios is small and the uncertainty regard-
ing options for their implementation is high. If research 
were to be initiated in Germany to obtain findings that could 
point the way to germline interventions, the legal ban on 
experiments on embryos would have to be amended first. 
Already for corresponding initiatives – but even more for 
further steps on this path – a broad societal forming of opin-
ion and debate are likely to be an important prerequisite, the 
strengthening of which is called for by many stakeholders 
from science and civil society. However, given the lack of 
reliable knowledge about success rates and potential side 
effects as well as correspondingly hypothetical application 
scenarios, the benefits of a debate on enabling germline in-
terventions are likely to remain limited at present. With re-
gard to the international level, agreements could be worked 
towards observing research on germline interventions by 
competent institutions and to refrain from clinical trials 
until the requirements regarding medical safety, ethical jus-
tifiability and societal acceptance are fulfilled.
